Wall Street analyst estimates for Kymera Therapeutics, Inc. (KYMR): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.
Consensus price target
$141.53 (+11 % vs price $127.51)
between $115.00 and $180.00 · 11 targets published in the last quarter
Closing price, Nov 2
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $100M | $98.4M – $113M | -$3.95 | 15 |
| 2027E | $42.0M | $5.7M – $56.5M | -$5.13 | 17 |
| 2028E | $41.6M | $36.9M – $45.4M | -$5.62 | 16 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 24 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 27 |
| Avg rating (−2 sell to +2 buy) | 0.89 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-25 | $-1.30 | ||
| 2026-10-29 | $-1.32 | $-1.26 | -4.8% |
| 2026-08-05 | $-0.62 | $-0.71 | +13.0% |
| 2026-04-30 | $-0.71 | $-0.89 | +20.2% |
| 2026-02-26 | $-0.97 | $-0.78 | -23.8% |
| 2025-11-04 | $-0.90 | $-0.71 | -26.8% |
| 2025-08-11 | $-0.95 | $-0.83 | -14.5% |
| 2025-05-09 | $-0.82 | $-0.92 | +10.9% |
Valuation Ratios
| Price / Book | 7.91 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $2.9M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Cost of Revenue | $205,000 | $825,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$205,000 | $2.1M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Research & Development | $17.7M | $37.2M | $62.1M | $137.0M | $164.2M | $189.1M | $240.2M | $316.6M |
| Selling, General & Admin | $3.8M | $8.0M | $18.2M | $36.3M | $43.8M | $55.0M | $63.5M | $68.2M |
| Operating Expenses | $21.5M | $45.1M | $80.3M | $173.4M | $208.1M | $244.1M | $308.7M | $388.6M |
| Operating Income | -$21.5M | -$42.2M | -$46.3M | -$100.5M | -$161.3M | -$165.5M | -$261.6M | -$349.4M |
| EBITDA | -$21.2M | -$40.4M | -$43.7M | -$97.6M | -$151.7M | -$143.2M | -$216.2M | -$303.1M |
| Interest Expense | $16,000 | $46,000 | $115,000 | $175,000 | $176,000 | $196,000 | $249,000 | $249,000 |
| Pre-tax Income | -$21.5M | -$41.2M | -$45.6M | -$100.2M | -$154.8M | -$147.0M | -$223.9M | -$311.6M |
| Income Tax | $43,859 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$21.5M | -$41.3M | -$45.6M | -$100.2M | -$154.8M | -$147.0M | -$223.9M | -$311.4M |
| EPS | -$0.48 | -$0.93 | -$0.99 | -$2.09 | -$2.87 | -$2.52 | -$2.98 | -$3.69 |
| EPS (Diluted) | -$0.48 | -$0.93 | -$0.99 | -$2.09 | -$2.87 | -$2.52 | -$2.98 | -$3.69 |
| Shares Outstanding (Diluted) | 44.5 M | 44.5 M | 44.6 M | 48.0 M | 53.9 M | 58.4 M | 75.0 M | 84.4 M |
Price
| Price | $127.51 (closing price, November 2, 2026) |
| Market Cap | $10.9B |
| Exchange | NASDAQ |
| Country | US |
Related companies: NRIX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of KYMR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks